Taiwan National Health Insurance Adminstration of the Ministry of Health and Welfare Approves Epclusa(R) (sofosbuvir/velpatasvir) for Reimbursement

Epclusa is the first approved single tablet regimen to treat all six major genotypes of hepatitis C virus (HCV) Epclusa will be made available to chronic hepatitis C patients via the National Health Insurance from 1 June 2019 TAIPEI, Taiwan, May 30, 2019 /PRNewswire/ -- Gilead Sciences,...

from PR Newswire: https://prn.to/2EJbCCV